Search…

Hengrui Medicine (01276.HK) spent 6.794 million yuan to repurchase 125,000 A-shares on August 12.

12/08/2026

Zhitong Finance App news, Hangzhou Huirui Pharmaceutical (01276.HK) announced that the company will spend 6.794 million yuan on August 12, 2026, to repurchase 125,000 A shares, with a repurchase price ranging from 54.15 to 54.41 yuan per share.

Latest

1 m ago

Today's southbound trading saw a net sell-off of 2.906 billion yuan. In the Hong Kong Stock Connect (Shanghai), Jian Tao Laminated Board and Alibaba-W saw net sell-offs of 613 million Hong Kong dollars and 526 million Hong Kong dollars respectively; Tencent Holdings had the largest net buy, amounting to 286 million Hong Kong dollars. In the Hong Kong Stock Connect (Shenzhen), Alibaba-W and Jian Tao Laminated Board experienced net sell-offs of 934 million Hong Kong dollars and 366 million Hong Kong dollars respectively; the largest net buy was 629 million Hong Kong dollars.

2 m ago

Eli Lilly: Calls for the rectification of entities that support sellers engaged in illegal activities.

2 m ago

Sunshine Oilsands (02012.HK) announced its second-quarter results, with a net loss attributable to shareholders of CAD 19.74 million, expanding by 896.47% year-on-year.

2 m ago

AI startup Lovable has completed a $400 million funding round, with a valuation of $13.3 billion.

2 m ago

Lu Kang Pharmaceutical (600789.SH): The for the chemical raw material drug, Methanesulfonate Lenvatinib, has been approved.

+852 - 60190728

Customer Support

Commercial Services